Latest news about Astal Laboratories
Astal Laboratories
81.40
+4.12(+5.33%)
Company Performance:
View Company Insights1D+5.33%
1M-1.09%
6M-0.77%
1Y-4.59%
5Y+789.62%
More news about Astal Laboratories
09Apr 26
Astal Laboratories Submits Quarterly Compliance Certificate for Q4 FY26
Astal Laboratories Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26 ended March 31, 2026. The certificate, issued by registrar BEETAL Financial & Computer Services, confirms proper dematerialization processes and adherence to regulatory requirements for securities handling and depositories management.
20Mar 26
Astral Laboratories Promoter ACESO Research Labs Acquires Additional 21,007 Shares
Astral Laboratories Limited disclosed that its promoter ACESO Research Labs LLP acquired 21,007 equity shares through open market transactions on BSE from March 11-19, 2026. The acquisition increased the promoter's shareholding from 4.64% to 4.69% of total share capital and from 4.45% to 4.50% of diluted capital. The disclosure was made under SEBI SAST Regulation 29(2) through Company Secretary Mahendra Kumar.
16Feb 26
Multiple Companies Submit Q3 FY26 Financial Results Including Astal Laboratories
Several companies reported their Q3 FY26 financial results with Astal Laboratories showing revenue of ₹5,223.53 lakhs and net profit of ₹235.73 lakhs, Coromandel Agro Products reporting income of ₹2,708.80 lakhs with net profit of ₹17.13 lakhs, and Objective Information Systems achieving revenue of ₹392.58 lakhs with net profit of ₹57.43 lakhs for the quarter ended December 31, 2025.
15Feb 26
Astal Laboratories Files Statement of Fund Utilization for Q3 FY26 with BSE
Astal Laboratories Limited filed its Q3 FY26 Statement of Deviation and Variation with BSE, reporting no deviations in fund utilization. The company raised Rs. 281.98 lakhs through preferential allotment on 12-08-2025 and has utilized Rs. 218.10 lakhs for capital expenditure, working capital, and general corporate purposes as originally planned. The Audit Committee and auditors provided no adverse comments on the fund deployment.
20Jan 26
Astal Laboratories Receives ₹29.57 Crore Investment Through Preferential Share Allotment
Astal Laboratories Limited completed a substantial preferential allotment of 29,56,666 equity shares on January 14, 2026, to non-promoter investors Suryanarayana Raju Rudraraju and Krishnaveni Rudraraju through a share swap arrangement. The transaction increased the company's equity share capital from ₹10.77 crores to ₹42.22 crores, representing an investment of approximately ₹29.57 crores. Suryanarayana Raju Rudraraju acquired 7.00% shareholding with 29,55,833 shares, while the remaining shares went to Krishnaveni Rudraraju. The company has complied with all SEBI regulatory requirements for substantial acquisition disclosures.
20Jan 26
Astal Laboratories Receives Substantial Acquisition Disclosure for 48.67 Lakh Shares Through Preferential Allotment
Astal Laboratories Limited received a substantial acquisition disclosure from Sesha Sai Nikhil Chintalapati, who acquired 48,67,348 equity shares through preferential allotment on January 14, 2026. This transaction increased his shareholding from 1.09% to 11.81% of the company's voting capital through a share swap arrangement. The acquisition expanded the company's equity share capital from ₹10.77 crores to ₹42.22 crores, with the disclosure made under SEBI regulations for substantial share acquisitions.
20Jan 26
Astal Laboratories: Kommera Harish Increases Stake to 6.67% Through Preferential Allotment
Kommera Harish acquired 26,98,140 equity shares of Astal Laboratories Limited through preferential allotment via share swap on January 14, 2026. His shareholding increased from 1.09% to 6.67% of voting capital. The transaction required disclosure under SEBI substantial acquisition regulations and resulted in significant changes to the company's capital structure.
20Jan 26
Astal Laboratories Completes ₹17.50 Crore Preferential Share Allotment to Non-Promoter Investors
Astal Laboratories Limited completed a preferential allotment of 17.50 lakh equity shares to non-promoter investors Vupparapalli Chandra Sekhar Reddy and Vupparapalli Pavani on January 14, 2026. The transaction involved warrant conversions and share swap arrangements, increasing the combined shareholding of both investors to 4.86% of total share capital. The company's equity capital expanded from ₹10.77 crores to ₹42.22 crores, with proper regulatory disclosures filed under SEBI regulations.
14Jan 26
Astal Laboratories Completes ₹277 Crore Sriven Pharmachem Acquisition Through Share Swap
Astal Laboratories Limited successfully acquired 100% stake in Sriven Pharmachem India Private Limited through a ₹277.17 crore share swap transaction. The acquisition involved allotment of 3.04 crore equity shares at ₹91 per share, making Sriven Pharmachem a wholly owned subsidiary. The target company, specializing in pharmaceutical intermediates and APIs, reported turnover of ₹102.70 crores in FY25.
30Dec 25
Astal Lab Signs LOI with Immuna Therapeutics for CAR-T Cell Therapy Rights
Astal Laboratories has partnered with Switzerland-based Immuna Therapeutics GmbH through a Letter of Intent for exclusive India rights to next-generation CAR-T cell therapies. The collaboration includes technology transfer and localization in India, with the company now projecting ₹3,000 crore in incremental revenue, representing a significant increase from previous estimates.
25Nov 25
Astal Laboratories Secures REACH Certification and Swiss Distribution Deal
Astal Laboratories Limited has obtained REACH compliance certification, enabling exports of specialty chemicals to the EU. The company also secured a Letter of Intent from a Swiss distributor for 60 tonnes of Piroctone Olamine, to be delivered between December 2025 and June 2026. These developments are expected to strengthen Astal's position in the European market and expand its international footprint.
09Nov 25
Astal Laboratories Expands Authorized Share Capital to Rs 50 Crore
Astal Laboratories Limited has increased its authorized share capital from Rs 20 crore to Rs 50 crore, as approved by shareholders at an EGM on November 6, 2025. The number of equity shares has risen from 2,00,00,000 to 5,00,00,000, maintaining a face value of Rs 10 per share. The company has informed the BSE about this development on November 9, 2025, in compliance with SEBI regulations.
07Nov 25
Astal Laboratories Holds EGM: Approves Share Capital Increase and Sriven Pharmachem Acquisition
Astal Laboratories Limited conducted an Extraordinary General Meeting on November 6, 2025, via video conferencing. The meeting focused on three key agenda items: increasing authorized share capital, acquiring a 100% stake in Sriven Pharmachem India Private Limited through equity share swap, and approving a related party transaction for the acquisition. The meeting was chaired by Dr. Radhakishore Pandrangi and attended by key directors. E-voting was conducted for all resolutions, with results to be announced within 48 hours.
03Oct 25
Astal Laboratories to Consider Share Capital Increase and Acquisition in Upcoming Board Meeting
Astal Laboratories Limited has scheduled a board meeting for October 9, 2025, to discuss significant matters. Key agenda items include potential increase in authorized share capital, consideration of preferential issue of equity shares or convertible warrants, final decision on acquiring Sriven Pharmachem India Private Limited, and preparations for an Extraordinary General Meeting. The company has implemented a trading window closure from October 1, 2025, until 48 hours after the declaration of Q2 FY2026 results. Corporate governance measures include appointing a scrutinizer for the e-voting process.
Industry Peers
Redington
MMTC
Elitecon International
MSTC
Ravindra Energy
BN Agrochem
Vintage Coffee & Beverages
TCC Concept
Creative Newtech
RRP Defense
242.24
(+2.59%)
70.02
(+2.88%)
29.93
(-0.20%)
629.50
(+10.72%)
146.84
(+7.97%)
275.55
(-1.80%)
155.84
(-2.26%)
349.20
(-2.16%)
722.70
(+2.50%)
714.35
(-1.00%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
